People: Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

17 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lewis, Alan 

Dr. Alan J. Lewis, Ph.D, is an Independent Director of Assembly Biosciences, Inc. Dr. Lewis is currently President, Chief Executive Officer and a director of Diavacs, a company developing curative treatments for type 1 diabetes. He recently was CEO and a director of Medistem, a developer of stem cell therapies that was acquired by Intrexon. Previously, Dr. Lewis was Chairman, President and CEO of cancer drug developer Ambit Biosciences, which was subsequently acquired by Daiichi Sankyo. Prior to Ambit, Dr. Lewis was President and CEO of the Juvenile Diabetes Research Foundation and President and CEO of stem cell company Novocell. Prior to Novocell, Dr. Lewis served as CEO and a director of Signal Pharmaceuticals until its acquisition by Celgene. Dr. Lewis then was named President of Celgene's Signal Research division in San Diego, where he directed its integrated drug discovery program in oncology and inflammation and served on Celgene's Corporate Executive Committee. Dr. Lewis also is on the board of directors for a number of companies, including BioMarin Pharmaceuticals, where he chairs the science and technology committee. For the 15 years prior to Signal and Celgene, Dr. Lewis held positions of increasing responsibility at Wyeth-Ayerst Research, culminating in his serving as Vice President of Research with responsibility for 550 scientists and staff. Dr. Lewis has contributed to advancing more than 20 molecules into clinical development and overseeing five investigational drugs that have reached the market; he has co-authored over 100 peer reviewed publications and is an inventor on several patents. Dr. Lewis holds a BSc from Southampton University and a PhD from the University of Wales, and he completed his postdoctoral training at Yale University.

Basic Compensation

Total Annual Compensation, USD 50,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 135,371
Fiscal Year Total, USD 185,371

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --